Toby Fox, PhD
Co-founder & Chief Scientific Officer
Dr. Fox is an immunologist trained at Max Plank Institute and Harvard Medical School. Before transitioning into Neutrolis, Toby had his own group a Principle investigator at University Medical Center Hamburg-Eppendorf. Toby is one of the most cited researchers in the field of Netosis with important contributions towards the biology of NETs and its implications in vascular and ischemic injuries.
Abdul Hakkim R, PhD
Co-founder, Chief Operating Officer & Interim CEO
Dr. Hakkim is an immunologist trained at Max Plank Institute and Harvard Medical School. Abdul along with Toby were the first graduate students at the Max Plank to work on the biology and implications of NETs in autoimmunity. At Harvard, Abdul worked on genetics of innate immunity before transitioning into an entrepreneur initially with Genma/Artus a spin-off out of Harvard and now Neutrolis.
Michael Singer, MD, PhD
Chief Medical Officer
Dr. Singer is a physician-scientist who has co-founded three successful healthcare companies. He previously served as a Director of Translational Medicine at Novartis, where he led development of three new biologics. Mike received his MD and PhD from Yale and completed residency at Harvard Medical School. He is a registered patent agent.
Angelene Prasanna, M. Pharm.
Senior Associate Scientist
Prasanna has completed Masters in Pharmaceutical Technology (Pharmacology) from Jadhavpur University and worked as a Research Associate in the DMPK Department, Aurigene Discovery Technologies for 7 years. At Neutrolis, Prasanna focuses on basic R&D, assay development, testing, validation and reporting.